中国卒中杂志 ›› 2016, Vol. 11 ›› Issue (02): 126-130.

• 专题综述 • 上一篇    下一篇

提高急性缺血性卒中静脉溶栓有效性和安全性的研究进展

吴岩峰,刘庆萍,丁红   

  1. 210003 南京医科大学第二附属医院神经科
  • 收稿日期:2015-10-19 出版日期:2016-02-20 发布日期:2016-02-20
  • 通讯作者: 丁红 hary2003@163.com

Study Progress of Improvement of Safety and Efficacy of Intravenous Thrombolysis on Acute Ischaemic Stroke

  • Received:2015-10-19 Online:2016-02-20 Published:2016-02-20

摘要:

重组组织型纤溶酶原激活剂(recombinant tissue plasminogen activator alteplase,rt-PA)是目 前急性缺血性卒中时间窗内静脉溶栓最有效的治疗药物,然而,静脉溶栓也伴随着出血转化、症状 性颅内出血风险的增加,导致患者预后不良,甚至死亡。因此,研究静脉溶栓治疗及预后的影响因素, 提高静脉溶栓治疗的有效性及安全性,对急性缺血性卒中患者的预后有着重大意义。

文章导读: 快速神经系统评估,尽早给予静脉溶栓,严格把握治疗指征,可以提高静脉溶栓治疗的有效性及安全性。

关键词: 急性缺血性卒中; 静脉溶栓; 重组组织型纤溶酶原激活剂; 有效性; 安全性

Abstract:

The recombinant tissue plasminogen activator alteplase (rt-PA) is the most effective therapeutic drug used in intravenous thrombolysis for patients with acute ischaemic stroke presenting within 4.5 h after symptom onset. Nevertheless, intravenous thrombolysis is accompanied with hemorrhagic transformation (HT), increased risk of symptomatic intracranial haemorrhage (sICH), poor prognosis and even deaths. Therefore, study on influential factors on treatment and prognosis and improvement of efficacy and safety of intravenous thrombolysis has important significance for prognosis of patients with acute ischemic stroke.

Key words: Acute ischaemic stroke; Intravenous thrombolysis; Recombinant tissue
plasminogen activator;
Efficacy; Safety